* Big discovery: Monocytes develop a chemical signature targeting them to the spinal cord in ALS patients. In SOD1 mutant mice, these signatures develop before the detection of disease. So the hope is that checking for this biomarker could be a valid way to detect the onset of disease. Also that checking for this level could be a way to verify presence of disease
* Hypothesis: If increased monocyte levels are causatory to the disease, or play a major causal role in the symptoms, then, suppressing their production could be a way to treat ALS. Some preliminary evidence that this may work, observed in lab animals. This may be tested in human trials later.
* ALS is a set of symptoms which may be proven in the future, to be caused by multiple causes. We need to test for these monocyte signatures in all known causes (multiple mutations, singly and possibly in combination)
* The human trial patients also need to be tested for the various mutations (or perhaps the patients should be sequenced). This can help detect if the cure works well only on certain detectable subsets of the disease.